Brent Saunders has returned to Bausch + Lomb as CEO in 2023, nearly four years after orchestrating the $63 billion sale of Allergan. Under his leadership, the company is now focusing on a $5.8 billion eye drug pipeline, aiming to revitalize its market position in the competitive ophthalmic sector. This strategic pivot comes at a time when the pharmaceutical industry is increasingly integrating artificial intelligence to enhance drug development and operational efficiencies.
As the industry grapples with evolving regulatory landscapes and market demands, Saunders’ insights into leveraging AI could provide critical advantages in streamlining processes and improving product quality. His perspectives on initiatives like TrumpRx, which aims to reduce drug prices, also highlight the ongoing dialogue around affordability and access in the pharmaceutical market. Stakeholders in regulatory, QA/QC, CMC, and sourcing roles will find Saunders’ approach particularly relevant as they navigate these complexities in their own operations.
Use the database as your supply chain compass →
